Not only does Summit-based Celgene Corp. look for cures to cancer, but it takes that mission personally. Alles serves on the board of Gilda's Club New York City, a nonprofit dedicated to helping families of cancer patients. Celgene has been at the forefront of the budding immunotherapy research field, a new type of cancer treatment that teaches the body's immune system to fight cancer. Celgene has finalized its $4.5 billion acquisition of Juno Therapeutics, which specializes in immunotherapy. And it recently opened a state-of-the-art treatment facility specializing in CAR T-cell therapy. The company is also partnering with the New Jersey Innovation Institute at the New Jersey Institute of Technology to create a training program in immunotherapy.